Avidity Biosciences Inc (NASDAQ: RNA) is 420.66% higher on its value in year-to-date trading and has touched a low of $4.82 and a high of $48.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RNA stock was last observed hovering at around $48.51 in the last trading session, with the day’s loss setting it -1.39%.
Currently trading at $47.12, the stock is 9.69% and 7.81% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.28 million and changing -2.87% at the moment leaves the stock 65.69% off its SMA200. RNA registered 693.27% gain for a year compared to 6-month gain of 76.88%. The firm has a 50-day simple moving average (SMA 50) of $43.7293 and a 200-day simple moving average (SMA200) of $28.63435.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 14.95% loss in the last 1 month and extending the period to 3 months gives it a 26.63%, and is 2.55% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.49% over the week and 5.09% over the month.
Avidity Biosciences Inc (RNA) has around 253 employees, a market worth around $5.52B and $10.60M in sales. Profit margin for the company is -2381.82%. Distance from 52-week low is 876.58% and -3.45% from its 52-week high. The company has generated returns on investments over the last 12 months (-20.60%).
Avidity Biosciences Inc quarterly earnings per share for the current quarter are estimated at -0.72 with sales reaching $4.27M over the same period.The EPS is expected to grow by 1.43% this year, but quarterly earnings will post 18.60% year-over-year. Quarterly sales are estimated to grow 132.10% in year-over-year returns.
282.0 institutions hold shares in Avidity Biosciences Inc (RNA), with institutional investors hold 102.16% of the company’s shares. The shares outstanding are 117.12M, and float is at 108.62M with Short Float at 11.03%. Institutions hold 97.17% of the Float.
The top institutional shareholder in the company is FMR LLC with over 16.16 million shares valued at $660.1 million. The investor’s holdings represent 18.5285 of the RNA Shares outstanding. As of 2024-06-30, the second largest holder is PRICE T ROWE ASSOCIATES INC /MD/ with 10.92 million shares valued at $445.94 million to account for 12.5173 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 8.81 million shares representing 10.0982 and valued at over $359.76 million, while BLACKROCK INC. holds 9.8868 of the shares totaling 8.62 million with a market value of $352.23 million.
Avidity Biosciences Inc (RNA) Insider Activity
Avidity Biosciences Inc disclosed in a document filed with the SEC on Sep 23 ’24 that McCarthy Teresa (Chief Human Resources Officer) sold a total of 13,153 shares of the company’s common stock. The trade occurred on Sep 23 ’24 and was made at $44.00 per share for $0.58 million. Following the transaction, the insider now directly holds 69018.0 shares of the RNA stock.
Still, SEC filings show that on Sep 23 ’24, Flanagan W. Michael (CSTO) disposed off 25,000 shares at an average price of $43.95 for $1.1 million. The insider now directly holds 72,718 shares of Avidity Biosciences Inc (RNA).
